Cogent Biosciences, Inc. Operating Lease Cost
Cogent Biosciences, Inc. (COGT) reported Operating Lease Cost of $3.29 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-17
- Cogent Biosciences, Inc. operating lease, cost for the quarter ending 2022-12-31 was -$3.23M, a 628.43% decline year-over-year.
- Cogent Biosciences, Inc. operating lease, cost for the quarter ending 2022-09-30 was $6.71M, a 995.92% increase year-over-year.
- Cogent Biosciences, Inc. operating lease, cost for the quarter ending 2022-06-30 was -$33.00K, a 105.45% decline year-over-year.
- Cogent Biosciences, Inc. operating lease, cost for the quarter ending 2022-03-31 was $612.00K, a 3.03% increase year-over-year.
- Cogent Biosciences, Inc. operating lease, cost for fiscal 2025 was $3.29M, a 0.00% change from fiscal 2024.
- Cogent Biosciences, Inc. operating lease, cost for fiscal 2024 was $3.29M, a 13.20% decline from fiscal 2023.
- Cogent Biosciences, Inc. operating lease, cost for fiscal 2023 was $3.80M, a 6.32% decline from fiscal 2022.
- Cogent Biosciences, Inc. operating lease, cost for fiscal 2022 was $4.05M, a 67.16% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.29M 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $3.29M 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $3.80M 10-K · filed 2026-02-17 | |||
| 2022-12-31 | -$3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $3.47M derived: sum of 2 quarters · filed 2025-02-25 | $3.44M derived: sum of 3 quarters · filed 2025-02-25 | $4.05M 10-K · filed 2025-02-25 |
| 2022-09-30 | $6.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.67M derived: sum of 2 quarters · filed 2022-11-14 | $7.29M 10-Q · filed 2022-11-14 | $7.90M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $579.00K 10-Q · filed 2022-08-09 | $1.19M derived: sum of 3 quarters · filed 2024-02-26 | $1.80M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $612.00K 10-Q · filed 2022-05-10 | $1.22M derived: sum of 2 quarters · filed 2024-02-26 | $1.84M derived: sum of 3 quarters · filed 2024-02-26 | $2.44M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $612.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.22M derived: sum of 2 quarters · filed 2024-02-26 | $1.83M derived: sum of 3 quarters · filed 2024-02-26 | $2.42M 10-K · filed 2024-02-26 |
| 2021-09-30 | $612.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.22M derived: sum of 2 quarters · filed 2021-11-10 | $1.81M 10-Q · filed 2021-11-10 | $2.52M derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-06-30 | $606.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $1.20M 10-Q · filed 2021-08-16 | $1.91M derived: sum of 3 quarters · filed 2022-03-15 | |
| 2021-03-31 | $594.00K 10-Q · filed 2021-05-12 | $1.31M derived: sum of 2 quarters · filed 2022-03-15 | ||
| 2020-12-31 | $713.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $2.08M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $1.37M 10-Q · filed 2020-11-09 | |||
| 2019-12-31 | $443.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $886.00K derived: sum of 2 quarters · filed 2021-03-16 | $1.33M derived: sum of 3 quarters · filed 2021-03-16 | $1.77M 10-K · filed 2021-03-16 |
| 2019-09-30 | $443.00K 10-Q · filed 2019-11-12 | $886.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.33M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $443.00K 10-Q · filed 2019-08-12 | $886.00K 10-Q · filed 2019-08-12 | ||
| 2019-03-31 | $443.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |